2-溴-5-(吡咯烷-1-基)吡嗪 | 1001050-21-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-溴-5-(吡咯烷-1-基)吡嗪
• 英文名称: 2-Bromo-5-(pyrrolidin-1-YL)pyrazine
• 英文别名: 2-bromo-5-pyrrolidin-1-ylpyrazine
• CAS: 1001050-21-0
• 化学式: C₈H₁₀BrN₃
• 分子量: 228.09
• InChiKey: OJPYLBAZSVUCNX-UHFFFAOYSA-N

物化性质

• 沸点：
  331.1±42.0 °C(Predicted)
• 密度：
  1.555±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  异丙醇频哪醇硼酸酯 、 2-溴-5-(吡咯烷-1-基)吡嗪 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 2-(Pyrrolidin-1-YL)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-YL)pyrazine
  参考文献：
  名称：

  NOVEL COMPOUNDS FOR DIAGNOSIS

  摘要：

  The present invention relates to novel compounds of formula (I), or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, that can be employed in the imaging of alpha-synuclein aggregates and determining an amount thereof. Furthermore, the compounds can be used for diagnosing a disease, disorder or abnormality associated with an alpha-synuclein aggregates (such as Parkinson's disease or such as multiple system atrophy (MSA)) determining a predisposition to such a disease, disorder or abnormality, prognosing such a disease, disorder or abnormality, monitoring the evolution of the disease in a patient suffering from such a disease, disorder or abnormality, monitoring the progression of such a disease, disorder or abnormality and predicting responsiveness of a patient suffering from such a disease, disorder or abnormality to a treatment thereof.

  公开号：

  WO2024126840A1
• 作为产物：
  描述：

  四氢吡咯 、 2,5-二溴吡嗪 在 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 以90 %的产率得到2-溴-5-(吡咯烷-1-基)吡嗪
  参考文献：
  名称：

  NOVEL COMPOUNDS FOR DIAGNOSIS

  摘要：

  The present invention relates to novel compounds of formula (I), or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, that can be employed in the imaging of alpha-synuclein aggregates and determining an amount thereof. Furthermore, the compounds can be used for diagnosing a disease, disorder or abnormality associated with an alpha-synuclein aggregates (such as Parkinson's disease or such as multiple system atrophy (MSA)) determining a predisposition to such a disease, disorder or abnormality, prognosing such a disease, disorder or abnormality, monitoring the evolution of the disease in a patient suffering from such a disease, disorder or abnormality, monitoring the progression of such a disease, disorder or abnormality and predicting responsiveness of a patient suffering from such a disease, disorder or abnormality to a treatment thereof.

  公开号：

  WO2024126840A1

文献信息

• HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Chytil Milan

  公开号：US20100204214A1

  公开（公告）日：2010-08-12

  Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了融合咪唑基化合物，其合成方法以及使用方法。本文提供的化合物对于治疗、预防和/或管理各种疾病，如神经系统疾病和代谢性疾病，具有用处。本文提供的化合物抑制组胺H3受体的活性，并调节各种神经递质的释放，如组胺、乙酰胆碱、去甲肾上腺素和多巴胺（例如在突触处）。本文还提供了含有这些化合物的药物配方及其使用方法。
• [EN] PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY<br/>[FR] DÉRIVÉS DE PYRROLIDINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION EN THÉRAPIE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2014140310A1

  公开（公告）日：2014-09-18

  The present invention relates to pyrrolidine derivatives of formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

  本发明涉及式(I)的吡咯烷衍生物，或其生理耐受盐。该发明涉及包含此类吡咯烷衍生物的药物组合物，以及利用此类吡咯烷衍生物进行治疗的用途。这些吡咯烷衍生物是GlyT1抑制剂。
• PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：EP2970215A1

  公开（公告）日：2016-01-20
• US20140275086A1
  申请人：——

  公开号：US20140275086A1

  公开（公告）日：2014-09-18
• US20140275087A1
  申请人：——

  公开号：US20140275087A1

  公开（公告）日：2014-09-18